3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
479
Carcinoma, Non-Small-Cell Lung
436
Prostatic Neoplasms
277
Lung Neoplasms
169
Stomach Neoplasms
138
Neoplasms
112
Squamous Cell Carcinoma of Head and Neck
109
Head and Neck Neoplasms
97
Neoplasm Metastasis
93
Esophageal Neoplasms
70
Ovarian Neoplasms
56
Pancreatic Neoplasms
41
Sarcoma
39
Urinary Bladder Neoplasms
38
Nasopharyngeal Carcinoma
32
Carcinoma, Squamous Cell
30
Triple Negative Breast Neoplasms
28
Carcinoma, Ovarian Epithelial
28
Adenocarcinoma of Lung
27
Adenocarcinoma
27
Esophageal Squamous Cell Carcinoma
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Carcinoma, Transitional Cell
23
Adenocarcinoma Of Esophagus
23
Breast Neoplasms, Male
22
Recurrence
21
Unspecified Adult Solid Tumor, Protocol Specific
20
Inflammatory Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Melanoma
18
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Gemcitabine
1
Gels
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urologic Diseases
×
Docetaxel
×
Clear all
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts